Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Gane

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Journal of Viral Hepatitis|December 10, 2016
Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirinS Alqahtani, R Ozaras, V Isakov, et al.
Clinical and Translational Gastroenterology|July 12, 2019
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular CarcinomaR K Kelley, E Gane, E Assenat, et al.
Journal of Viral Hepatitis|October 6, 2015
Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patientsK Visvanathan, T Lang, K Ryan, et al.
Alimentary Pharmacology & Therapeutics|October 13, 2017
HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patientsD Wong, M Littlejohn, L Yuen, et al.
Journal of Viral Hepatitis|March 16, 2017
Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertensionN Afdhal, G T Everson, J L Calleja, et al.
Trials|July 18, 2018
Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trialA J Wade, J S Doyle, E Gane, et al.
Alimentary Pharmacology & Therapeutics|March 10, 2018
Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patientsW-L Chuang, J Jia, H L Y Chan, et al.
Hepatology (Baltimore, Md.)|November 3, 2011
Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or CY-F Liaw, J-D Jia, H L Y Chan, et al.
Journal of Gastroenterology and Hepatology|April 21, 2007
Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection, G W McCaughan, M Omata, et al.
Journal of Viral Hepatitis|January 7, 2015
The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2A Hatzakis, V Chulanov, A C Gadano, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Journal of Viral Hepatitis|December 10, 2016
Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirinS Alqahtani, R Ozaras, V Isakov, et al.
Clinical and Translational Gastroenterology|July 12, 2019
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular CarcinomaR K Kelley, E Gane, E Assenat, et al.
Journal of Viral Hepatitis|October 6, 2015
Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patientsK Visvanathan, T Lang, K Ryan, et al.
Alimentary Pharmacology & Therapeutics|October 13, 2017
HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patientsD Wong, M Littlejohn, L Yuen, et al.
Journal of Viral Hepatitis|March 16, 2017
Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertensionN Afdhal, G T Everson, J L Calleja, et al.
Trials|July 18, 2018
Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trialA J Wade, J S Doyle, E Gane, et al.
Alimentary Pharmacology & Therapeutics|March 10, 2018
Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patientsW-L Chuang, J Jia, H L Y Chan, et al.
Hepatology (Baltimore, Md.)|November 3, 2011
Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or CY-F Liaw, J-D Jia, H L Y Chan, et al.
Journal of Gastroenterology and Hepatology|April 21, 2007
Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection, G W McCaughan, M Omata, et al.
Journal of Viral Hepatitis|January 7, 2015
The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2A Hatzakis, V Chulanov, A C Gadano, et al.
Pageof 6